EUCTR2007-003056-12-IT进行中（未招募）1 期
A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WITH ADVANCED BILIARY TRACT CANCER (GALLBLADDER CANCER, CANCER OF THE EXTRAHEPATIC BILE DUCT, INTRAHEPATIC CHOLANGIOCARCINOMA AND AMPULLARY CARCINOMA) - VANGOGH
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ASTRAZENECA
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of informed consent 2.Male or Female aged 18 years and over 3.Histologically or citologically-confirmed advanced (unresectable or metastatic) biliary tract cancer (gallbladder cancer, cancer of the extrahepatic bile duct, intrahepatic cholangiocarcinoma and ampullary carcinoma) excluding small cell (oat cell) carcinoma of the hepatobiliary tract. 4.Patients must have measurable or evaluable but non-measurable disease, defined as follows: - Measurable Disease - Patients with measurable disease as defined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria, i.e., the presence of at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm using spiral Computed Tomography (CT) scan. Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules, palpable lymph nodes). - Evaluable but Non-measurable Disease - Patients with all lesions below the limits defined above for measureable disease (i.e., longest diameter < 20 mm with conventional techniques or < 10 mm with spiral CT) excluding those patients with only a primary non-measurable lesion and/or with only non-evaluable cancer such as bone metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis of the skin or lung, previously irradiated lesions not in progression, or peritoneal carcinomatosis < 10 mm in diameter with conventional imaging techniques. 5.Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 3 months before the trial entry is accepted). 6.WHO performance status 0 to 2: patients must have a WHO PS ≤ 2 7.Life expectancy of at least 12 weeks. 8.Negative pregnancy test for women of childbearing potential 9.Provision of informed consent for biomarker research (optional)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Histologically or citologically-confirmed small cell (oat cell) carcinoma of the hepatobiliary tract is to be excluded. 2.Patients must not have received prior systemic therapy for advanced (unresectable or metastatic) disease; prior chemotherapy in the adjuvant setting within 3 months before the trial entry is accepted. 3.Prior treatment with VEGFR TKIs (previous treatment with bevacizumab [Avastin] is permitted) 4.Prior unanticipated severe reaction to GEMCITABINE therapy or known sensitivity to GEMCITABINE. 5.Radiation therapy within 4 weeks before the start of study therapy, not including local palliative radiation. Prior radiotherapy is accepted as long as target lesions have not been irradiated. Lesions that have received radiation in the advanced setting cannot be included as target lesions unless clear tumour progression has been documented in the lesions since the end of radiation therapy 6.Major surgery within 4 weeks, or incompletely healed surgical incision before starting study therapy or serious, non-healing wound, ulcer, or bone fracture. Insertion of a vascular access device is not considered major/minor surgery. 7.Inadequate end-organ function 8.Known brain metastases or carcinomatous meningitis. Patients with known brain metastases should be excluded from this clinical trial unless asymptomatic or with evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days. 9.Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator?s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol
研究者
相似试验
进行中（未招募）
不适用
A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAPY-NAÏVE PATIENTS WITH ADVANCED (STAGE IIIB OR IV) NON-SMALL CELL LUNG CANCER (NSCLC) AND POOR PERFORMANCE STATUS - INSTEPon-Small Cell Lung CancerEUCTR2004-004206-25-CZAstraZeneca AB200
进行中（未招募）
1 期
A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAPY-NAÏVE PATIENTS WITH ADVANCED (STAGE IIIB OR IV) NON-SMALL CELL LUNG CANCER (NSCLC) AND POOR PERFORMANCE STATUS - INSTEPon-Small Cell Lung CancerEUCTR2004-004206-25-IEAstraZeneca AB201
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPYEUCTR2010-019134-27-CZChelsea Therapeutics, Inc250
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, METHOTREXATE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SAFETY, AND TOLERABILITY OF CH-4051 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE SHOWN AN INADEQUATE RESPONSE TO METHOTREXATE MONOTHERAPYRhuematoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019134-27-BGChelsea Therapeutics, Inc250
进行中（未招募）
1 期
A PHASE II, MULTI CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, DOSE-ESCALATION, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF CK-1827452 IN PATIENTS WITH STABLE HEART FAILURE.EUCTR2006-001871-39-GBCytokinetics, Inc56